IJCS | Volume 32, Nº2, May/June 2019

289 3. Lavanchy D. Evolving epidemiology of hepatitis C virus. ClinMicrobiol Infect. 2011;17(2):107–15. 4. Zignego AL, Ferri C, Pileri SA, Caini P, Bianchi FB. Extrahepatic manifestations of Hepatitis C Virus infection: A general overview and guidelines for a clinical approach. Dig Liver Dis. 2007;39(1):2–17. 5. Ambrosino P, Lupoli R, Di MinnoA, Tarantino L, Spadarella G, Tarantino P, et al. The risk of coronary artery disease and cerebrovascular disease in patients with hepatitis C: A systematic review and meta-analysis. Int J Cardiol. 2016 Oct 15;221:746–54. 6. Petit J, Bour J, Galland-jos C, Minello A, Verges B, Guiguet M, et al. Risk factors for diabetes mellitus and early insulin resistance in chronic hepatitis C. J Hepatol. 2001;35(2):279-83. 7. Boddi M, Abbate R, Chellini B, Giusti B, Giannini C, Pratesi G, et al. Hepatitis C virus RNA localization in human carotid plaques. J Clin Virol. 2010;47(1):72–5. 8. Fung G, Luo H, Qiu Y, Yang D, Mc Manus B. Myocarditis. Circ Res. 2016;118(3): 496-514. 9. Matsumori A, Ohashi N, Hasegawa K, Sasayama S. Hepatitis C virus infection and heart disease - a multicenter study in Japan. Jpn Circ J. 1998;62(5):389–91. 10. Falk RH, Hershberger RE. The dilated, restrictive and infiltrative cardiomyopathies. In: Mann DL, Zipes DP, Libby P, Bonow RO, Braunwald E. Heart disease. A textbook of cardiovascular medicine. 10a.ed . Philadelphia: Elselvier; 2015. p.1551-73. 11. Prati D, Poli F, Farma E, Picone A, Porta E, Mattei C De, et al. Multicenter study on hepatitis C virus infection in patients with dilated cardiomyopathy. J Med Virol. 1999;120:116–20. 12. Reis FJ, Viana M, Oliveira M, Sousa TA, Paraná R. Prevalence of hepatitis C and B virus infection in patients with idiopathic dilated cardiomyopathy in Brazil : a pilot study. BJID. 2007;11(3):318–21. 13. Sanchez MJ, Bergasa N V. Hepatitis C associated cardiomyopathy : Potential pathogenic mechanisms and clinical implications. Med Sci Monit. 2008;14(5):55–64. 14. Maron BJ, Olivotto L. Hypetrophic cardimyopathy. In: Mann DL, Zipes DP, Libby P, Bonow RO, Braunwald E. Heart Disease. A textbook of cardiovascular medicine. 10a.ed. Philadelphia: Elselvier; 2015. p.1574-88. 15. Zardi EM, Abbate A, Zardi DM, Dobrina A, Margiotta D, Tassel BW Van, et al. Cirrhotic cardiomyopathy. JACC. 2010;56(7):539–49. 16. Mozos I. Arrhythmia risk in liver cirrhosis. World J Hepatol. 2015;7(4):662–72. 17. Hoeper MM, Krowka MJ, Strassburg CP. Portopulmonary hypertension and hepatopulmonary syndrome. Lancet. 2004;363(9419):1461–8. 18. Bernardi M, Calandra S, Colantoni A, Trevisani F, Raimondo ML, Sica G, et al. Q–T interval prolongation in cirrhosis: prevalence, relationship with severity, and etiology of the disease and possible pathogenetic factors. Hepatology. 1998;27(1):28–34. 19. Nordin C, Kohli A, Beca S, Zaharia V, Grant T, Leider J, et al. Importance of hepatitis C coinfection in the development of QT prolongation in HIV-infected patients. J Electrocardiol. 2006;39(2):199–205. 20. WongcharoenW,SuaklinS,TantisirivitN,PhrommintikulA,Chattipakorn N. QT dispersion in HIV-infected patients receiving combined antiretroviral therapy. AnnNoninvasive Electrocardiol. 2014;19(6):561–6. 21. Lee H, Choi EK, Rhee TM, et al. Cirrhosis is a risk factor for atrial fibrillation: A nationwide, population-based study. Liver Int. 2017;37(11):1660–7. 22. Zenghua MA, Miyamoto A, Lee SS. Role of altered beta-adrenoceptor signal transduction in the pathogenesis of cirrhotic cardiomyopathy in rats. Gastroenterology. 1996;110(4):1191-8. 23. Wong F, Girgrah N, Graba J, Allidina Y, Liu P, Blendis L. The cardiac response to exercise in cirrhosis. Gut. 2001;49(2):268-75. 24. Rudzinski W, Waller AH, Prasad A, Sood S, Gerula C, Samanta A, Koneru B, et al. New index for assessing the chronotropic response in patients with end-stage liver disease who are undergoing dobutamine stress echocardiography. Liver Transpl. 2012;18(3):355-70. 25. Matusik D, Bednarkiewicz Z, Paprotna K. Cardiotoxic properties of interferon. Pol Arch Med Wewn. 2007;117(1-2):49-52. 26. Sonnenblick M, Rosin A. Cardiotoxicity of lnterferon. Chest. 1991;99(3):557–61. 27. Durante-Mangoni E, Iossa D, Pinto D, De Vincentiis L, Ragone E, Utili R. Safety and efficacy of peginterferon alpha plus ribavirin in patients with chronic hepatitis C and coexisting heart disease. Dig Liver Dis. 2011;43(5):411–5. 28. Almawardy R, Elhammady W, Mousa N, Abotaleb S. Is combination therapy for chronic hepatitis C toxic for cardiac function? Hepat Mon. 2012;12(8):8–13. 29. Gane EJ, Stedman CA, Hyland RH, Ding X, Svarovskaia E, Symonds WT, et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med. 2013;368(1):34–44. 30. Keating GM. Sofosbuvir: A review of its use in patients with chronic hepatitis C. Drugs. 2014;74(10):1127–46. 31. U.S.FDA Hepatitis Update - Important safety information: Harvoni and Sovaldi. [Cited in 2017 Feb 23].Available from: http://content. govdelivery.com/accounts/USFDA/bulletins/f97c71. 32. Fontaine H, Lazarus A, Pol S, Pecriaux C, Bagate F, Sultanik P, et al. Bradyarrhythmias associated with sofosbuvir treatment. N Engl J Med. 2015;373(19):1886–8. 33. Zamora JA, Espinoza LA. Sinus bradycardia induced by darunavir ritonavir in a patient with acquired immunodefciency syndrome. Infection. 2017; 45(5):721–3. 34. Back DJ, Burger DM. Interaction between amiodarone and sofosbuvir- based treatment for hepatitis C virus infection: Potential mechanisms and lessons to be learned. Gastroenterology. 2015;149(6):1315–7. 35. Millard DC, Strock CJ, Carlson CB, Aoyama N, Juhasz K, Goetze TA, et al. Identification of drug – drug interactions in vitro : A case study evaluating the effects of sofosbuvir and amiodarone on hiPSC-derived cardiomyocytes. Toxicol Sci. 2016;154(1):174-82. 36. Caldeira D, Rodrigues FB, DuarteMM, Sterramino C, BarraM, Gonçalves N, et al. Cardiac harms of sofosbuvir : systematic review and meta- analysis. Drug Saf. 2018;41(1):77-86. 37. Durante-Mangoni E, Parrella A, Vitrone M, Rago A, Pafundi PC, Nigro G, et al. Electrophysiological adverse effects of direct acting antivirals in patients with chronic hepatitis C. J Clin Pharmacol. 2017;57(7): 924-30. 38. Hagiwara S, Nishida N, Watanabe T. Outcome of combination therapy with sofosbuvir and ledipasvir for chronic type C liver disease. Oncology. 2017;92(Suppl 1):3–9. Rezende et al. Cardiac disorders in chronic hepatitis C Int J Cardiovasc Sci. 2019;32(3)283-289 Review Article This is an open-access article distributed under the terms of the Creative Commons Attribution License